Center for Artificial Intelligence in Drug Discovery, Case Western Reserve University School of Medicine, Cleveland, Ohio.
Center for Clinical Informatics Research and Education, The MetroHealth System and Departments of Medicine, Pediatrics, and Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, Ohio.
JAMA Netw Open. 2024 Oct 1;7(10):e2439444. doi: 10.1001/jamanetworkopen.2024.39444.
In adults, diagnoses of new-onset type 2 diabetes (T2D) have increased following diagnosis with COVID-19, but whether this occurs in children is unclear.
To determine whether risk of incident T2D diagnosis is increased during the 6 months after SARS-CoV-2 infection among children.
DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study used electronic health records from the TriNetX analytics platforms between January 1, 2020, and December 31, 2022. Pediatric patients aged 10 to 19 years without preexisting diabetes were eligible for inclusion. Data were analyzed from August 15 to September 15, 2023, with supplemental analyses January 20 and August 8 to 13, 2024.
Diagnosis of COVID-19 or a non-COVID-19 respiratory infection.
New diagnosis of T2D compared by risk ratios (RRs) and 95% CIs at 1, 3, and 6 months after index infection.
The main study population included 613 602 patients, consisting of 306 801 with COVID-19 (mean [SD] age at index, 14.9 [2.9] years; 52.8% female) and 306 801 with other respiratory infections (ORIs) but no documented COVID-19 (mean [SD] age at index, 14.9 [2.9] years; 52.6% female) after propensity score matching. Risk of a new diagnosis of T2D was significantly increased from day of infection to 1, 3, and 6 months after COVID-19 diagnosis compared with the matched cohort with ORIs (RR at 1 month, 1.55 [95% CI, 1.28-1.89]; RR at 3 months: 1.48 [95% CI, 1.24-1.76]; RR at 6 months: 1.58 [95% CI, 1.35-1.85]). Similar results were found in the subpopulation classified as having overweight or obesity (RR at 1 month: 2.07 [95% CI, 1.12-3.83]; RR at 3 months: 2.00 [95% CI, 1.15-3.47]; RR at 6 months: 2.27 [95% CI, 1.38-3.75]) and the hospitalized subpopulation (RR at 1 month: 3.10 [95% CI, 2.04-4.71]; RR at 3 months: 2.74 [95% CI, 1.90-3.96]; RR at 6 months: 2.62 [95% CI, 1.87-3.66]). Similar elevation in risk was found at 3 and 6 months when excluding patients diagnosed during the interval from the index date to 1 month after infection.
In this retrospective cohort study of children and adolescents aged 10 to 19 years, the risk of an incident diagnosis of T2D was greater following a COVID-19 diagnosis than in children diagnosed with ORIs. Further study is required to determine whether diabetes persists or reverses later in life.
在成年人中,COVID-19 诊断后新发 2 型糖尿病 (T2D) 的诊断有所增加,但在儿童中是否如此尚不清楚。
确定儿童 SARS-CoV-2 感染后 6 个月内新发 T2D 诊断的风险是否增加。
设计、地点和参与者:本回顾性队列研究使用了 2020 年 1 月 1 日至 2022 年 12 月 31 日期间来自 TriNetX 分析平台的电子健康记录。年龄在 10 至 19 岁、无糖尿病前期的儿科患者符合纳入条件。数据分析于 2023 年 8 月 15 日至 9 月 15 日进行,补充分析于 2024 年 1 月 20 日和 8 月 8 日至 13 日进行。
COVID-19 或非 COVID-19 呼吸道感染的诊断。
与索引感染后 1、3 和 6 个月相比,T2D 的新诊断风险比 (RR) 和 95%置信区间 (CI)。
主要研究人群包括 613602 名患者,其中 306801 名患有 COVID-19(指数时的平均[SD]年龄为 14.9[2.9]岁;52.8%为女性)和 306801 名患有其他呼吸道感染(但无记录的 COVID-19)在倾向评分匹配后。与 ORI 匹配队列相比,COVID-19 诊断后从感染日到 1、3 和 6 个月,新发 T2D 的风险显著增加(1 个月时的 RR,1.55[95%CI,1.28-1.89];3 个月时的 RR:1.48[95%CI,1.24-1.76];6 个月时的 RR:1.58[95%CI,1.35-1.85])。在根据超重或肥胖(1 个月时的 RR:2.07[95%CI,1.12-3.83];3 个月时的 RR:2.00[95%CI,1.15-3.47];6 个月时的 RR:2.27[95%CI,1.38-3.75])和住院亚群(1 个月时的 RR:3.10[95%CI,2.04-4.71];3 个月时的 RR:2.74[95%CI,1.90-3.96];6 个月时的 RR:2.62[95%CI,1.87-3.66])中也发现了类似的风险升高。当排除从索引日期到感染后 1 个月期间诊断的患者时,在 3 个月和 6 个月时也发现了类似的风险升高。
在这项针对 10 至 19 岁儿童和青少年的回顾性队列研究中,COVID-19 诊断后新发 T2D 的风险高于 ORI 诊断的儿童。需要进一步研究以确定糖尿病是否在以后的生活中持续存在或逆转。